KBC Group
ROIV icon

KBC Group’s Roivant Sciences ROIV Stock Holding History

KBC Group’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.97M Buy
81,138
+68,056
+520% +$2.47M 0.01% 595
2026
Q2 		$463K Buy
13,082
+1,350
+12% +$39.9K ﹤0.01% 810
2026
Q1 		$325K Sell
11,732
-802
-6% -$20.6K ﹤0.01% 854
2025
Q4 		$272K Buy
12,534
+1,867
+18% +$36.8K ﹤0.01% 813
2025
Q3 		$161K Hold
10,667
– – ﹤0.01% 1005
2025
Q2 		$120K Sell
10,667
-5,609
-34% -$60.8K ﹤0.01% 1095
2025
Q1 		$164K Buy
16,276
+402
+3% +$4.35K ﹤0.01% 1178
2024
Q4 		$188K Buy
15,874
+5,839
+58% +$69K ﹤0.01% 1165
2024
Q3 		$116K Hold
10,035
– – ﹤0.01% 1193
2024
Q2 		$106K Buy
10,035
+3,268
+48% +$35.8K ﹤0.01% 1132
2024
Q1 		$71K Hold
6,767
– – ﹤0.01% 1328
2023
Q4 		$76K Sell
6,767
-774
-10% -$7.54K ﹤0.01% 1238
2023
Q3 		$88K Buy
+7,541
New +$85.3K ﹤0.01% 1068

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

KBC Group's ROIV Position: Q3 2026 in Review

KBC Group increased its Roivant Sciences (ROIV) stake by 520% in Q3 2026, buying an estimated $2.47M and bringing the position to 81,138 shares worth $2.97M. The position accounts for 0.01% of the portfolio, ranked #595.

KBC Group first reported a position in ROIV in Q3 2023 and has held it in 13 quarters since. 395 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • KBC Group held 81,138 shares of Roivant Sciences worth $2.97M as of Q3 2026.
  • KBC Group bought 68,056 Roivant Sciences shares in Q3 2026, an estimated $2.47M.
  • Roivant Sciences made up 0.01% of KBC Group's portfolio in Q3 2026, its #595 holding.
  • KBC Group first reported a position in Roivant Sciences in Q3 2023 and has held it in 13 quarters since.
  • 395 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.